| Autor: |
Chao Sun, Xin Zhou, Jing Wang, Jingjue Mao, Hongfeng Guo |
| Předmět: |
|
| Zdroj: |
European Journal of Clinical & Medical Oncology; 2012, Vol. 4 Issue 2, p91-94, 4p, 2 Color Photographs, 2 Charts |
| Abstrakt: |
Bortezomib has shown significant efficacy in the treatment of patients with relapse multiple meloma (MM). We report a case of a 75-yearold man relapsed multiple extramedullary plasmocytoma (EPM) of MM in different locations without evidence of bone marrow disease progression. The patient was managed with bortezomib-based therapy. Bortezomib in the dose of 1.3 mg/m2 was administered at days 1, 4, 8, and 11 of each 21-day cycle. Dexamethasone at a dose of 20 mg/24 h and thalidomide at a dose of 200 mg/24 h were given at days 1-4, 8-11, and every day, respectively. After 6 months follow-up, the patient showed no signs of local recurrence or progression of the disease. The use of bortezomib-based therapy could be a reliable, safe, and effective alternative for treating extramedullary relapse of MM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
